Medigene (LSE:0QGJ) - Aandelenkoers, Nieuws & Analyse

0QGJ Overzicht aandelen

A biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. Meer informatie

0QGJ fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	1/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 16.13% per jaar groeien

De winst is de afgelopen 5 jaar met 11.2% per jaar gegroeid

Risicoanalyse

De winst zal naar verwachting de komende drie jaar met gemiddeld 4.1% per jaar dalen.

Aandelen zijn zeer illiquide

Heeft minder dan 1 jaar cash runway

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

+ 2 meer risico's

Medigene AG Concurrenten

Oncimmune Holdings

AIM:ONC

UK£17.2m

Tissue Regenix Group

AIM:TRX

UK£40.6m

ProBiotix Health

OFEX:PBX

UK£10.7m

Aptamer Group

AIM:APTA

UK£6.1m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Medigene
Historische aandelenkoersen
Huidige aandelenkoers	€1.95
52 Week Hoogtepunt	€5.84
52 Week Laag	€1.95
Bèta	0.86
11 maand verandering	-14.10%
3 maanden verandering	-19.42%
1 Jaar Verandering	-46.72%
33 jaar verandering	-74.81%
5 jaar verandering	-85.11%
Verandering sinds IPO	-95.39%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	0QGJ	GB Biotechs	GB Markt
7D	-12.6%	1.5%	2.2%
1Y	-46.7%	-17.9%	8.8%

Rendement versus industrie: 0QGJ presteerde slechter dan de UK Biotechs -sector, die het afgelopen jaar een rendement van -17.9 % opleverde.

Rendement versus markt: 0QGJ presteerde slechter dan UK Market, dat het afgelopen jaar een rendement van 8.8 % opleverde.

Prijsvolatiliteit

Is 0QGJ's price volatile compared to industry and market?
0QGJ volatility
0QGJ Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.6%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.2%
10% least volatile stocks in GB Market	2.6%

Stabiele aandelenkoers: De aandelenkoers van 0QGJ is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van 0QGJ in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1994	87	Selwyn Ho	www.medigene.com

Medigene AG Samenvatting

Hoe verhouden de winst en inkomsten van Medigene zich tot de beurswaarde?
0QGJ fundamentele statistieken
Marktkapitalisatie	€29.90m
Inkomsten(TTM)	-€15.93m
Inkomsten(TTM)	€7.45m

4.0x

P/S-verhouding

-1.9x

Koers/Winstverhouding

Is 0QGJ overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
0QGJ resultatenrekening (TTM)
Inkomsten	€7.45m
Kosten van inkomsten	€1.49m
Brutowinst	€5.95m
Overige uitgaven	€21.89m
Inkomsten	-€15.93m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.08
Brutomarge	79.94%
Nettowinstmarge	-213.98%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde 0QGJ op de lange termijn?

Bekijk historische prestaties en vergelijking

0QGJ Overzicht aandelen

Beloningen

Risicoanalyse

Medigene AG Concurrenten

AIM:ONC

UK£17.2m

AIM:TRX

UK£40.6m

OFEX:PBX

UK£10.7m

AIM:APTA

UK£6.1m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Medigene AG Presents Unique Approach for Use of Optimal T Cell Receptors in TCR-Guided Modalities At Cell 2024

Medigene AG Presents Progress on KRAS Library and UniTope & TraCR Technology at ESMO 2024

Second quarter 2024 earnings released: €0.15 loss per share (vs €0.17 loss in 2Q 2023)

Medigene AG Reaffirms Revenue Guidance for the Year 2024

Medigene AG Expands Patent Portfolio with the Patent Grant for its NY-ESO-1/LAGE 1a Targeted T Cell Receptor in China

New major risk - Financial position

Recent updates

Medigene AG Presents Unique Approach for Use of Optimal T Cell Receptors in TCR-Guided Modalities At Cell 2024

Medigene AG Presents Progress on KRAS Library and UniTope & TraCR Technology at ESMO 2024

Second quarter 2024 earnings released: €0.15 loss per share (vs €0.17 loss in 2Q 2023)

Medigene AG Reaffirms Revenue Guidance for the Year 2024

Medigene AG Expands Patent Portfolio with the Patent Grant for its NY-ESO-1/LAGE 1a Targeted T Cell Receptor in China

New major risk - Financial position

Medigene AG to Report First Half, 2024 Results on Aug 14, 2024

Medigene Presents Efficient 6-Day TCR-T Therapy Production Process with High Stemness

New minor risk - Shareholder dilution

Medigene AG, Annual General Meeting, Jun 24, 2024

Medigene AG Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS

Medigene Ag Maintains Earnings Guidance for 2024

Medigene Presents Superior TCR-T Cell Functionality by Inclusion of A Costimulatory Switch Protein

Medigene AG Presents Streamlined 6-Day, High Stemness Tcr-T Therapy Production Process

Medigene AG Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024

Medigene AG Secures European Patent for Its iM-TCR Technology

Full year 2023 earnings released: €0.66 loss per share (vs €0.34 loss in FY 2022)

Medigene Ag Provides Earnings Guidance for 2024

Medigene AG to Report Fiscal Year 2023 Results on Mar 28, 2024

New minor risk - Financial data availability

Medigene AG Announces Indication Selection for the Clinical Development of Its Lead 3Rd Generation Tcr-T Therapy Program in Solid Tumors

Medigene AG Maintains Financial Guidance for the Fiscal Year 2023

Medigene AG Presents First Pre-Clinical Data of Optimal Affinity TCR Targeting mKRAS G12V Combined with a PD1-41BB Costimulatory Switch Protein Showing

Medigene to Present New Pre-Clinical Data for Pipeline TCR-T Therapies At the ESMO Congress 2023

Medigene AG Provides Revenue Guidance for 2023

New major risk - Financial position

Second quarter 2023 earnings released: €0.17 loss per share (vs €0.097 loss in 2Q 2022)

Full year 2022 earnings released: €0.34 loss per share (vs €0.41 loss in FY 2021)

Medigene AG to Report Q3, 2023 Results on Oct 26, 2023

Medigene AG Maintains Revenue Guidance for the Fiscal Year 2022

Medigene AG Announces Appointment of Selwyn Ho as Member of the Executive Management Board with Effect of 25 July 2022

Medigene AG Announces Publication Details Augmentation of PRAME-Specific TCR-4 by PD1-41BB Switch Receptor

Medigene AG to Report Q3, 2022 Results on Nov 02, 2022

No longer forecast to breakeven

Medigene AG Reports Preliminary Efficacy and Immune Monitoring Data of Phase I of Phase I/II MDG1011 Trial in Blood Cancers

Medigene AG Achieves Positive Preliminary Results in Phase I of Phase I/II Trial of TCR-T Therapy MDG1011 in Blood Cancers

Medigene's PD1-41BB Switch Receptor Improves TCR-T Cell Functionality Against Solid Tumors

Forecast to breakeven in 2022

Medigene Confirms Revenue Guidance for 2021

Medigene AG Provides Earnings Guidance for the Year 2021

Advisor has left the company

Full year 2020 earnings released: €1.18 loss per share (vs €0.81 loss in FY 2019)

Medigene AG Announces Executive Changes

Medigene AG to Report Fiscal Year 2020 Final Results on Mar 25, 2021

Medigene AG Presents Further Encouraging Results from the Follow-Up of Acute Myeloid Leukemia Patients

Medigene AG Announces Discontinuation of MDG1021 Development Program

New 90-day high: €4.53

Medigene AG Announces Board Changes

Medigene AG, Annual General Meeting, Jun 24, 2021

Medigene AG Provides Update on MDG1011 Phase I/II clinical trial

Earnings released

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Medigene AG Samenvatting

4.0x

-1.9x

Inkomsten en omzet